{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:38:33Z","timestamp":1780439913646,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dupilumab and tralokinumab are interleukin-binding monoclonal antibodies used to treat systemic atopic disease. Use of these medications in management of atopic dermatitis (AD) is known to cause conjunctivitis. Dupilumab therapy has also been associated with more severe ocular surface disease, which has not previously been described in association with tralokinumab. This report describes a case of tralokinumab-associated conjunctivitis and peripheral ulcerative keratitis and reviews the spectrum and proposed mechanisms of ocular surface disease triggered by these medications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 61-year-old male with no rheumatologic or ocular history presented with bilateral papillary conjunctivitis and right eye peripheral ulcerative keratitis (PUK). PUK was arrested using oral corticosteroids and doxycycline, and long-term control of papillary conjunctivitis was achieved using topical tacrolimus ointment, allowing continuation of effective AD management with tralokinumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This case report documents ulcerative keratitis occurring in association with tralokinumab therapy for AD, which has previously been described with dupilumab but not tralokinumab. This report demonstrates the need for vigilant ocular surface monitoring for patients on tralokinumab and illustrates successful management and long-term control of adverse ocular events associated with this medication.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12348-024-00394-1","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T10:03:28Z","timestamp":1713261808000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Peripheral ulcerative keratitis associated with tralokinumab therapy: a case report and review of IL-13 inhibitor-associated ocular surface disease"],"prefix":"10.1186","volume":"14","author":[{"given":"Nenita","family":"Maganti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Whittier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"issue":"4","key":"394_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/ICO.0000000000003162","volume":"42","author":"T Mickevicius","year":"2023","unstructured":"Mickevicius T, Pink AE, Bhogal M, O\u2019Brart D, Robbie SJ, Dupilumab-Induced (2023) Tralokinumab-Induced, and Belantamab Mafodotin-Induced adverse ocular Events-Incidence, etiology, and management. Cornea 42(4):507\u2013519","journal-title":"Cornea"},{"issue":"8","key":"394_CR2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1097\/ICO.0000000000002854","volume":"41","author":"M Phylactou","year":"2022","unstructured":"Phylactou M, Jabbour S, Ahmad S, Vasquez-Perez A (2022) Corneal perforation in patients under treatment with Dupilumab for atopic dermatitis. Cornea 41(8):981\u2013985","journal-title":"Cornea"},{"issue":"6","key":"394_CR3","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjd.21867","volume":"187","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Merola JF, Silverberg JI et al (2022) Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol 187(6):888\u2013899","journal-title":"Br J Dermatol"},{"issue":"12","key":"394_CR4","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1038\/s41433-020-01379-9","volume":"35","author":"MZ Popiela","year":"2021","unstructured":"Popiela MZ, Barbara R, Turnbull AMJ et al (2021) Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye (Lond) 35(12):3277\u20133284","journal-title":"Eye (Lond)"},{"issue":"4","key":"394_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2340\/00015555-3121","volume":"99","author":"LU Ivert","year":"2019","unstructured":"Ivert LU, Wahlgren CF, Ivert L, Lundqvist M, Bradley M (2019) Eye complications during Dupilumab treatment for severe atopic dermatitis. Acta Derm Venereol 99(4):375\u2013378","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"394_CR6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1136\/bjophthalmol-2019-315010","volume":"104","author":"Y Nahum","year":"2020","unstructured":"Nahum Y, Mimouni M, Livny E, Bahar I, Hodak E, Leshem YA (2020) Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol 104(6):776\u2013779","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"394_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.17869","volume":"181","author":"B Akinlade","year":"2019","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M et al (2019) Conjunctivitis in dupilumab clinical trials. Br J Dermatol 181(3):459\u2013473","journal-title":"Br J Dermatol"},{"issue":"5","key":"394_CR8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/ICO.0000000000002461","volume":"40","author":"A Bohner","year":"2021","unstructured":"Bohner A, Topham C, Strunck J et al (2021) Dupilumab-Associated Ocular Surface Disease: clinical characteristics, treatment, and Follow-Up. Cornea 40(5):584\u2013589","journal-title":"Cornea"},{"issue":"5","key":"394_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ophtha.2021.11.002","volume":"129","author":"PM Far","year":"2022","unstructured":"Far PM, Quinn MP, Johnson D (2022) Bilateral Peripheral Ulcerative Keratitis Associated with Dupilumab. Ophthalmology 129(5):561","journal-title":"Ophthalmology"},{"key":"394_CR10","doi-asserted-by":"crossref","unstructured":"Asher MI, Montefort S, Bj\u00f6rkst\u00e9n B et al (2007) Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys [published correction appears in Lancet. ;370(9593):1128]. Lancet. 2006;368(9537):733\u2013743","DOI":"10.1016\/S0140-6736(06)69283-0"},{"issue":"1 Pt 1","key":"394_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0091-6749(99)70536-1","volume":"103","author":"H Williams","year":"1999","unstructured":"Williams H, Robertson C, Stewart A et al (1999) Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and allergies in Childhood. J Allergy Clin Immunol 103(1 Pt 1):125\u2013138","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"394_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1203475416685077","volume":"21","author":"JN Mayba","year":"2017","unstructured":"Mayba JN, Gooderham MJ (2017) Review of atopic dermatitis and topical therapies. J Cutan Med Surg 21(3):227\u2013236","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"394_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/00003226-200009000-00008","volume":"19","author":"MR Dana","year":"2000","unstructured":"Dana MR, Qian Y, Hamrah P (2000) Twenty-five-year panorama of corneal immunology: emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. Cornea 19(5):625\u2013643","journal-title":"Cornea"},{"issue":"2","key":"394_CR14","first-page":"252","volume":"17","author":"K Hassanpour","year":"2022","unstructured":"Hassanpour K, ElSheikh H, Arabi R (2022) Peripheral ulcerative keratitis: a review. J Ophthalmic Vis Res 17(2):252\u2013275","journal-title":"J Ophthalmic Vis Res"},{"issue":"6","key":"394_CR15","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.survophthal.2021.02.013","volume":"66","author":"Y Gupta","year":"2021","unstructured":"Gupta Y, Kishore A, Kumari P et al (2021) Peripheral ulcerative keratitis. Surv Ophthalmol 66(6):977\u2013998","journal-title":"Surv Ophthalmol"},{"key":"394_CR16","doi-asserted-by":"publisher","first-page":"108458","DOI":"10.1016\/j.exer.2021.108458","volume":"204","author":"BF Gomes","year":"2021","unstructured":"Gomes BF, Santhiago MR (2021) Biology of peripheral ulcerative keratitis. Exp Eye Res 204:108458","journal-title":"Exp Eye Res"},{"key":"394_CR17","doi-asserted-by":"publisher","first-page":"152269","DOI":"10.1016\/j.semarthrit.2023.152269","volume":"63","author":"D Clarke","year":"2023","unstructured":"Clarke D, Sartor L, Do V, Manolios N, Swaminathan S, Samarawickrama C (2023) Biologics in peripheral ulcerative keratitis. Semin Arthritis Rheum 63:152269","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"394_CR18","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","volume":"154","author":"AD Treister","year":"2018","unstructured":"Treister AD, Kraff-Cooper C, Lio PA (2018) Risk factors for Dupilumab-Associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol 154(10):1208\u20131211","journal-title":"JAMA Dermatol"},{"issue":"1","key":"394_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/00003226-199001000-00013","volume":"9","author":"J Tauber","year":"1990","unstructured":"Tauber J, de la Sainz M, Hoang-Xuan T, Foster CS (1990) An analysis of therapeutic decision making regarding immunosuppressive chemotherapy for peripheral ulcerative keratitis. Cornea 9(1):66\u201373","journal-title":"Cornea"},{"issue":"10086","key":"394_CR20","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M et al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389(10086):2287\u20132303","journal-title":"Lancet"},{"issue":"24","key":"394_CR21","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E et al (2016) Two phase 3 trials of Dupilumab versus Placebo in atopic dermatitis. N Engl J Med 375(24):2335\u20132348","journal-title":"N Engl J Med"},{"issue":"1","key":"394_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","volume":"143","author":"A Wollenberg","year":"2019","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E et al (2019) Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol 143(1):135\u2013141","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"394_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E et al (2021) Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 184(3):437\u2013449","journal-title":"Br J Dermatol"},{"issue":"3","key":"394_CR24","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.19573","volume":"184","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Toth D, Bieber T et al (2021) Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 184(3):450\u2013463","journal-title":"Br J Dermatol"},{"issue":"6","key":"394_CR25","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/ICO.0000000000002262","volume":"39","author":"P Liberman","year":"2020","unstructured":"Liberman P, Shifera AS, Berkenstock M (2020) Dupilumab-Associated conjunctivitis in patients with atopic dermatitis. Cornea 39(6):784\u2013786","journal-title":"Cornea"},{"issue":"12","key":"394_CR26","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1001\/jamadermatol.2018.3427","volume":"154","author":"RM Levine","year":"2018","unstructured":"Levine RM, Tattersall IW, Gaudio PA, King BA (2018) Cicatrizing Blepharoconjunctivitis Occurring during Dupilumab Treatment and a proposed algorithm for its management. JAMA Dermatol 154(12):1485\u20131486","journal-title":"JAMA Dermatol"},{"issue":"7","key":"394_CR27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/09546634.2019.1711010","volume":"32","author":"DH Lee","year":"2021","unstructured":"Lee DH, Cohen LM, Yoon MK, Tao JP (2021) Punctal stenosis associated with dupilumab therapy for atopic dermatitis. J Dermatolog Treat 32(7):737\u2013740","journal-title":"J Dermatolog Treat"},{"key":"394_CR28","doi-asserted-by":"publisher","first-page":"100848","DOI":"10.1016\/j.ajoc.2020.100848","volume":"19","author":"G Li","year":"2020","unstructured":"Li G, Berkenstock M, Soiberman U (2020) Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis. Am J Ophthalmol Case Rep 19:100848","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"2","key":"394_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/ijd.14573","volume":"59","author":"C Wang","year":"2020","unstructured":"Wang C, Kraus CN, Patel KG, Ganesan AK, Grando SA (2020) Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients\u2019 records. Int J Dermatol 59(2):253\u2013256","journal-title":"Int J Dermatol"},{"issue":"3","key":"394_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","volume":"8","author":"A Maudinet","year":"2019","unstructured":"Maudinet A, Law-Koune S, Duretz C, Lasek A, Modiano P, Tran THC (2019) Ocular Surface diseases Induced by Dupilumab in severe atopic dermatitis. Ophthalmol Ther 8(3):485\u2013490","journal-title":"Ophthalmol Ther"},{"key":"394_CR31","doi-asserted-by":"crossref","unstructured":"Barnett BP, Afshari NA (2020) Dupilumab-Associated Mucin Deficiency (DAMD) [published correction appears in Transl Vis Sci Technol. ;9(8):21]. Transl Vis Sci Technol. 2020;9(3):29","DOI":"10.1167\/tvst.9.3.29"},{"issue":"5","key":"394_CR32","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/bjd.17538","volume":"180","author":"DS Bakker","year":"2019","unstructured":"Bakker DS, Ariens LFM, van Luijk C et al (2019) Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol 180(5):1248\u20131249","journal-title":"Br J Dermatol"},{"issue":"9","key":"394_CR33","doi-asserted-by":"publisher","first-page":"e612","DOI":"10.1111\/jdv.17210","volume":"35","author":"G Calabrese","year":"2021","unstructured":"Calabrese G, Gambardella A, Licata G, Di Brizzi EV, Alfano R, Argenziano G (2021) Dupilumab and conjunctivitis: a case series of twenty patients. J Eur Acad Dermatol Venereol 35(9):e612\u2013e614","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"394_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.alit.2018.12.012","volume":"68","author":"K Fukuda","year":"2019","unstructured":"Fukuda K, Ishida W, Kishimoto T, Fukushima A (2019) Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis. Allergol Int 68(3):383\u2013384","journal-title":"Allergol Int"},{"issue":"8","key":"394_CR35","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.oftal.2019.04.013","volume":"94","author":"J Roca-Gin\u00e9s","year":"2019","unstructured":"Roca-Gin\u00e9s J, Rahhal-Ortu\u00f1o M, Torres-Navarro I, Rodr\u00edguez-Serna M, Navarro-Mira M\u00c1 (2019) Cyclosporine 0.1% (Ikervis\u00ae) treatment in steroid-dependent dupilumab-associated conjunctivitis. Arch Soc Esp Oftalmol (Engl Ed) 94(8):396\u2013399","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"issue":"10","key":"394_CR36","first-page":"590","volume":"101","author":"W Frazier","year":"2020","unstructured":"Frazier W, Bhardwaj N (2020) Atopic dermatitis: diagnosis and treatment. Am Fam Physician 101(10):590\u2013598","journal-title":"Am Fam Physician"},{"issue":"9","key":"394_CR37","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/14740338.2021.1939673","volume":"20","author":"W Francuzik","year":"2021","unstructured":"Francuzik W, Alexiou A, Worm M (2021) Safety of dupilumab in patients with atopic dermatitis: expert opinion. Expert Opin Drug Saf 20(9):997\u20131004","journal-title":"Expert Opin Drug Saf"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-024-00394-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-024-00394-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-024-00394-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T10:03:33Z","timestamp":1713261813000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-024-00394-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["394"],"URL":"https:\/\/doi.org\/10.1186\/s12348-024-00394-1","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All review and evaluation of protected patient health information was HIPAA compliant and adhered to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient provided written consent for the use of patient information and images for the purposes of scientific publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}